Abstract:
Methods for regulating angiogenesis by modulating the activity of 20-HETE are disclosed. Further disclosed are methods of inhibiting cancer and tumor cell growth by exposing the cancer and tumor cells to 20-HETE inhibitors.
Abstract:
Novel processes for the preparation of imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines are described.
Abstract:
The invention provides a method of increasing the retention of a scale inhibitor on a rock material comprising preconditioning the rock material with a positively charged bridging agent and contacting the rock material with said scale inhibitor.
Abstract:
Compounds having formula (I), wherein R 3 is selected from H, OH and NH 2 ; R 30 is selected from =O and =S; W is -C(=O)-, -S(=O)-, or -S(O) 2 -; or W may be -CH 2 - if X is -C(=O)-; X is selected from -CH 2 -, -N(R 4 )-, and -O-, except that when W is -CH 2 -, X is -C(=O)-; Y is a bond or -C(R 40 )(R 45 )-; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and R 1 , R 2 , R 24 and R 25 are as defined in the specification.
Abstract:
Compounds having the formula (I), wherein R 3 is selected from H, OH and NH 2 ; R 30 is selected from =O and =S; W is -C(=O)-, -S(=O)-, or -S(O) 2 -; or W may be -CH 2 - if X is -C(=O)-; X is selected from -CH 2 -, -N(R 4 )-, and -O-, except that when W is -CH 2 -, X is -C(=O)-; Y is a bond or -C(R 40 )(R 45 )-; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 and X 11 are selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.
Abstract:
The present invention provides methods of treating a mammal, such as a mammal suffering from benign prostate hyperplasia, prophylactically or therapeutically. The methods comprise administering a prophylactic or therapeutic nucleic acid operably linked to a promoter to a mammal in need of prophylactic or therapeutic treament of its prostate via transurethral injection, the use of a prostate-specific promoter and/or the use of a targeting moiety that preferentially binds to a prostate cell, instead of a non-prostate cell, whereupon the prophylactic or therapeutic nucleic acid is expressed in cells of the prostate of the mammal, thereby prophylactically or therapeutically treating the mammal.
Abstract:
The present invention provides a circuit board connector which has a low profile and which occupies a small area on a circuit board without having any effect on the insertion of mating connectors even in cases where screws of which the length of the threaded section is greater than the combined total of the thickness of the lower wall of the housing and the thickness of the circuit board are used. The housing (10) of the connector (1) has latching surfaces on the inside of the upper wall (16) which forms the cavities (14) into which mating connectors are inserted. Furthermore, screw-attachment sections (26) which have holes (28) that accommodate screws (5) used to fasten the connector (1) to the circuit board are formed as integral parts of the housing (10) on the underside of the rear wall (12) of the housing (10). The front walls (30) which delineate the holes (28) are thicker than the opposite rear walls (32). When the screws (5) are screwed into the holes (28), the rear walls (32) expand slightly; accordingly the screws (5) move rearward so that there is no protrusion of the screws (5) into the interiors of the cavities (14).
Abstract:
A receptacle contact in which the rigitidy of the spring-loaded contacting arms changes continuously. The receptacle contact (1) has a spring-loaded contact member (22) which is formed by bending backward a base wall (12) into a space (23) of a box-shaped contact section (10) and an extension (32) formed by bending back an inner end of the spring-loaded contact member (22) forward. Extension (32) has a flat section (36) which engages with the base wall (12) when spring-loaded contact member (22) is deformed; with the area of engagement or contact being changed gradually. In order to prevent excessive stress in bend (34), at a front end of extension (32), a projection (40) is made by bending the tip of the extension toward spring-loaded contact member (22). And in order to prevent excessive stress in bend (24), a projection (26) is made by bending a portion of base wall (12) upward in the area of bend (24).
Abstract:
Embodiments of the present disclosure provide method and apparatus for session restoration. A method performed by a network node comprises receiving a first request for setting up a session with required quality of service (QoS) from an application node. The method further comprises sending a first response comprising error information and subscription information of an existing session including a subscription identifier to the application node.
Abstract:
The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.